More layoffs in pharma

imagesPOST SUMMARY: Amgen said it plans to reduce its global workforce by 12% to 15% and close facilities in two states as part of a restructuring that aims to focus resources on developing new drugs. In an industry where layoffs have become the norm one has to wonder if “the right people” are being let go vs. the pharma lifers who continue to hang on to paychecks. Continue reading »

FDA out of touch with eHealth consumers

tumblr_maxdsj0vxu1r5yyy5o1_400POST SUMMARY: Consumers today are not going to make a healthcare decision based on any one piece of advertising or information. Healthcare decisions are made by collecting information, mostly online, and listening to physicians who patients feel are still the best sources of health recommendations. Continue reading »

DTC marketing is slow to change

dtcchangePOST SUMMARY: The news this week that more than half of all biopharma employees are looking to leave the industry should be a wake-up call for senior managers, but it may be too late as both digital and DTC pharma marketing continue to struggle to transform the organization from “big pharma” mindset to operating with a sense of urgency with a focus more on patients. Continue reading »

More than half pharma employes want to leave

2014 engagementEmployees in the U.S. biotech and pharma industries express significant interest in accepting or seeking out a new employment offer, according to a new Randstad Pharma Engagement Study.  The study reveals that within the next six months one-half (51%) of biotech/pharma workers are likely to seek out a job in a different company or organization, as compared to 38 percent of all employees polled.  Furthermore, should they receive an enticing job offer from another company, 66 percent of biotech/pharma employees are likely to accept, compared to 44 percent of all employees polled. Continue reading »

Drug costs high but still better than alternatives

drugcostsPOST SUMMARY: (via Boston Globe) Fewer than 4 percent of patients use specialty drugs, but they account for 25 percent of total drug spending.  “The impact of the specialty tier benefit design falls disproportionately on patients who are living with diseases and conditions that are serious and life-threatening,” said Marialanna Lee, Northeast Region state government affairs director for the Leukemia & Lymphoma Society. Often the specialty drug is the only one available for these conditions, she said. “It’s going to cost more in the long run,” predicts Patricia Ferland Weltin, executive director and founder of the Rare Disease United Foundation. If denied drugs that keep them well, she says, “They’re going to end up in the E.R, they’re going to end up sick, costing more money than if they took the drug. . . . Continue reading »

Want to work in pharma? Pirates need not apply

innovat-150x150POST SUMMARY: A pirate can function within a bureaucracy. Pirates support one another and support their leader in the accomplishment of a goal. A pirate can stay creative and on task in a difficult or hostile environment. A pirate can act independently and take intelligent risks, but always within the scope of the greater vision and the needs of the greater team.  One could argue that today the biopharma industry is in dire need of a lot more pirates. Continue reading »

Patient Insights: Opportunities for pharma (MS)

insights_ideasPOST SUMMARY: Patient insights provide valuable opportunities for pharma marketers to get closer to their customers (patients) but only if DTC marketers are listening and act quickly to provide tools and health information that drive patient needs and brand objectives. Continue reading »

Development process for biopharma websites

processPOST SUMMARY: Pharma product websites are too important to let an agency develop in a vacuum. DTC marketers need to be involved from strategy through testing and optimization yet very few organizations don’t invest the time and effort to develop a great online experience. Continue reading »